We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.76B
1-Year Est. Return 62.41%
This Fund
S&P 500
This Quarter Est. Return
+6.07%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$4.05B
AUM Growth
+$503M
Cap. Flow
+$330M
Cap. Flow %
8.14%
Top 10 Hldgs %
55.84%
Holding
654
New
120
Increased
131
Reduced
191
Closed
155
Avg Time Held Equity + Options
4.2 quarters
Top 10 Avg Time Held Equity + Options
1.2 quarters
Top 20 Avg Time Held Equity + Options
1.3 quarters
Avg Time Held Equity only
4.5 quarters
Top 10 Avg Time Held Equity only
1.2 quarters
Top 20 Avg Time Held Equity only
1.3 quarters

Top Buys

Rank Stock Value
1
K icon
Kellanova
K
+$269M
2
SRCL icon
Stericycle Inc
SRCL
+$141M
3
MRO icon
Marathon Oil Corporation
MRO
+$108M
4
CHX icon
ChampionX
CHX
+$103M
5
SPR icon
Spirit AeroSystems
SPR
+$95.3M

Top Sells

Rank Stock Value
1
ETRN icon
Equitrans Midstream Corporation Common Stock
ETRN
+$149M
2
CERE icon
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$81.8M
3
SWN icon
Southwestern Energy Company
SWN
+$56.7M
4
UNP icon
Union Pacific
UNP
+$24.2M
5
X icon
US Steel
X
+$20.2M

Sector Composition

Rank Sector Weight
1 Energy 20.91%
2 Technology 19.62%
3 Healthcare 14.36%
4 Industrials 11.13%
5 Consumer Staples 9.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
INCY icon
201
Incyte
INCY
$22.8B
$1.58M 0.04%
23,871
-3,679
-13% -$235K
2023 Q1
6 quarters
BKD icon
202
Brookdale Senior Living
BKD
$2.43B
$1.57M 0.04%
231,502
-20,033
-8% -$143K
2023 Q4
3 quarters
KALV icon
203
DELISTED
KalVista Pharmaceuticals
KALV
$1.57M 0.04%
135,552
+12,592
+10% +$158K
2024 Q1
2 quarters
TFX icon
204
Teleflex
TFX
$5.33B
$1.57M 0.04%
6,343
+2,343
+59% +$547K
2024 Q2
1 quarter
SLN icon
205
Silence Therapeutics
SLN
$618M
$1.56M 0.04%
85,701
+8,861
+12% +$165K
2022 Q2
9 quarters
IDYA icon
206
IDEAYA Biosciences
IDYA
$3.49B
$1.54M 0.04%
48,604
-11,446
-19% -$434K
2022 Q3
8 quarters
INTR icon
207
Inter&Co
INTR
$3.41B
$1.53M 0.04%
+229,524
New +$1.59M
2024 Q3
0 quarters
BAP icon
208
Credicorp
BAP
$30.5B
$1.5M 0.04%
+8,311
New +$1.42M
2024 Q3
0 quarters
POLEU icon
209
Andretti Acquisition Corp II Unit
POLEU
$1.5M 0.04%
+150,000
New +$1.5M
2024 Q3
0 quarters
VFC icon
210
VF Corp
VFC
$6.18B
$1.5M 0.04%
+75,000
New +$1.26M
2024 Q3
0 quarters
NKTR icon
211
Nektar Therapeutics
NKTR
$1.36B
$1.5M 0.04%
76,722
+7,127
+10% +$136K
2023 Q3
4 quarters
EL icon
212
Estee Lauder
EL
$35B
$1.5M 0.04%
+15,000
New +$1.42M
2024 Q3
0 quarters
BBIO icon
213
BridgeBio Pharma
BBIO
$12.9B
$1.49M 0.04%
58,596
+22,096
+61% +$580K
2024 Q2
1 quarter
ADC icon
214
Agree Realty
ADC
$8.24B
$1.49M 0.04%
19,759
-15,404
-44% -$1.09M
2019 Q4
19 quarters
ONC icon
215
BeOne Medicines Ltd
ONC
$39.9B
$1.48M 0.04%
+6,600
New +$1.19M
2024 Q3
0 quarters
IONS icon
216
Ionis Pharmaceuticals
IONS
$7.36B
$1.48M 0.04%
36,957
-5,638
-13% -$262K
2022 Q1
10 quarters
ORIC icon
217
Oric Pharmaceuticals
ORIC
$1.25B
$1.47M 0.04%
143,320
+28,954
+25% +$286K
2022 Q2
9 quarters
EXR icon
218
Extra Space Storage
EXR
$28.3B
$1.47M 0.04%
8,147
-17,167
-68% -$2.9M
2021 Q1
14 quarters
CROX icon
219
Crocs
CROX
$5.63B
$1.45M 0.04%
+10,000
New +$1.36M
2024 Q3
0 quarters
CDLX icon
220
Cardlytics
CDLX
$13M
$1.44M 0.04%
45,000
-29,478
-40% -$1.64M
2023 Q4
3 quarters
KROS icon
221
Keros Therapeutics
KROS
$237M
$1.44M 0.04%
24,752
+2,299
+10% +$114K
2022 Q1
10 quarters
WEL icon
222
DELISTED
Integrated Wellness Acquisition Corp
WEL
$1.43M 0.04%
121,140
-3,914
-3% -$45.8K
2022 Q1
10 quarters
TEVA icon
223
Teva Pharmaceutical Industries Limited
TEVA
$48B
$1.43M 0.04%
79,132
+28,236
+55% +$494K
2023 Q3
4 quarters
HALO icon
224
Halozyme
HALO
$12.7B
$1.41M 0.03%
24,683
-9,000
-27% -$516K
2022 Q1
10 quarters
KIDS icon
225
OrthoPediatrics
KIDS
$569M
$1.41M 0.03%
52,022
+3,925
+8% +$119K
2022 Q1
10 quarters
7 8
9
10 11

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return
JCM
Janney Capital Management Pittsburgh, Pennsylvania $1.59B AUM 23.25% 1-Year Est. Return
MPM
Meritage Portfolio Management Overland Park, Kansas $1.51B AUM 26.61% 1-Year Est. Return

UBS O'Connor's Q3 2024 Portfolio in Review

As of Q3 2024, UBS O'Connor held 654 positions worth $4.05B, up 14% from $3.55B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

UBS O'Connor deployed $330M of net new capital in Q3 2024, opening 120 new positions and adding to 131 existing holdings. Its largest new stake was Kellanova: 3,778,689 shares worth $305M.

By sector, the portfolio is most concentrated in Energy at 21% of assets, down from 27% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was US Steel, an estimated $20.2M trimmed.

  • UBS O'Connor's largest Q3 2024 buy was Kellanova: 3,778,689 shares worth $305M.
  • UBS O'Connor added most to Stericycle Inc in Q3 2024, an estimated $141M increase.
  • UBS O'Connor's biggest Q3 2024 reduction was US Steel, cutting an estimated $20.2M.
  • UBS O'Connor fully exited Equitrans Midstream Corporation Common Stock in Q3 2024, selling an estimated $149M.
  • UBS O'Connor's ten largest holdings make up 56% of its $4.05B portfolio in Q3 2024.
  • UBS O'Connor opened 120 new positions and closed 155 in Q3 2024.
  • UBS O'Connor's portfolio value rose 14% quarter-over-quarter to $4.05B.

Based on UBS O'Connor's 13F filing for Q3 2024, filed 14 Nov 2024.